This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Radius Health, Inc.
Drug Names(s): BA058 SC, BA058 SQ, BA058 Subcutaneous, BA058-SC, BIM44058, ITM-058
BioMedTracker has separate drug profiles for the subcutaneous and transdermal formulations of BA058.
BA058 (formerly known as BIM44058) is an analog of PTHrP (parathyroid hormone-related protein). PTHrP shares the same N-terminal end as parathyroid hormone and therefore it can bind to the same receptor (the Type I PTH receptor).
Ipsen and Teijin
In July 2003, Ipsen and Teijin enter into an agreement to development and market four Ipsen products in Japan and a Teijin's anti-gout agent, TMX-67 for the treatment of gout in Europe.
The four products from Ipsen are a Glucagon-like peptide-1 analogue (GLP-1, code name: BIM51077) for which Teijin has been granted co-exclusive rights in Japan, a type 2-receptor selective somatostatin analogue (SSTR-2, code name: BIM23190), a parathyroid hormone 1-34 fragment analogue (PTH, code name: BIM44058), and a sustained-release formulation of a somatostatin analogue (Somatuline Autogel), for which Teijin has been granted exclusive rights in Japan. Teijin will develop the analogues of GLP-1, SSTR-2, PTH and Somatuline Autogel as treatments for type II diabetes, diabetic retinopathy, severe osteoporosis, and acromegaly, respectively.
Ipsen and Radius
In December 2005, Radius (formerly known as Nuvios) announced that it entered into a licensing...See full deal structure in Biomedtracker
Partners: Ipsen SA Teijin Pharma Limited Novartis AG
Additional information available to subscribers only: